Lanreotide

July 20, 2023

Lanreotide is a somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours.
Lanreotide is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)


Status:In Mass Production
Unit:5mg,10mg,1g/customized
Capacity: 1kg/month

Request a Quick Quote

Raw Lanreotide powder (108736-35-2) video

Lanreotide Description

Lanreotide is a somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours.

Lanreotide is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Lanreotide Specifications

Product NameLanreotide
Chemical Name(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-(naphthalen-2-yl)propanamido)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
Brand NameSomatuline; Lanreotide; Ipstyl; BIM 23014; Somatulin; Lanreotide Autogel.
Drug ClassPeptide
CAS Number108736-35-2
InChIKeyPUDHBTGHUJUUFI-SCTWWAJVSA-N
Molecular FormulaC54H69N11O10S2
Molecular Weight1096.33g
Monoisotopic Mass1095.467 g/mol
Melting Point 180-185°C
Freezing PointN/A
Biological Half-Life2 hours
ColorWhite powder
Solubility slightly soluble in DMSO and methanol
Storage Temperature 0 – 4 C for short term (days to weeks), or -20 C for long term (months).
ApplicationLanreotide is a somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours.

Contact Us

Polypeptide Peptide dosage calculator